Oryzon Genomics, S.A.

https://www.oryzon.com

Oryzon Genomics, S.A. is a clinical-stage biopharmaceutical company and a European leader in the development of epigenetics-based therapeutics. Founded in 2000 in Barcelona, Spain, the company's core mission is to leverage epigenetics to discover and develop innovative personalized medicines for patients suffering from cancer and central nervous system (CNS) disorders. Its operational headquarters are located in Cornellà de Llobregat, Barcelona, Spain.

Oryzon's therapeutic strategy focuses on targeting lysine specific demethylase 1 (LSD1), a histone modifying enzyme implicated in various human diseases. The company's pipeline includes two primary compounds in clinical development: iadademstat, a selective LSD1 inhibitor for oncology and hematology indications such as acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS-optimized LSD1 inhibitor for CNS and psychiatric disorders, including borderline personality disorder, schizophrenia, and autism spectrum disorder. Additionally, Oryzon has ORY-4001, a selective HDAC6 inhibitor, in preclinical development.

In recent news, Oryzon Genomics received a U.S. patent allowance for its vafidemstat BPD treatment in March 2026 and announced a new U.S. patent covering iadademstat combinations with venetoclax. The company also received EMA clearance for an essential thrombocythemia trial in February 2026. Leadership was strengthened with the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer for CNS Programs in February 2026. Oryzon continues to advance its clinical programs, including addressing FDA feedback on the Phase III protocol for vafidemstat in borderline personality disorder, with plans to revise and resubmit. Carlos Buesa serves as the Chief Executive Officer.

Latest updates

Oryzon to Present Updated AML Data at EHA Congress

Event summary

  • Oryzon Genomics will present updated data from clinical trials of iadademstat for acute myeloid leukemia (AML) at the European Hematology Association (EHA) Congress in June.
  • The company will also participate in Bio-Equity Europe, Foro Medcap, the Jefferies Healthcare Conference, the Spring European MidCap Event, and the BIO International Convention.
  • Preliminary data from trials combining iadademstat with azacitidine and venetoclax showed a 100% overall response rate (ORR) in 1L AML.
  • Oryzon is advancing a broader epigenetics pipeline, including ORY-4001 for CMT and ALS.

The big picture

Oryzon’s progress with iadademstat, particularly its combination therapies, positions it as a potential player in the competitive AML treatment landscape. The company’s reliance on investigator-initiated studies (IIS) and collaborations with institutions like OHSU and the NCI, while enabling rapid development, also introduces dependencies and potential IP complexities. The upcoming EHA presentation represents a key inflection point for the program’s future.

What we're watching

Clinical Data
The EHA presentation will be critical in assessing the continued efficacy and safety of iadademstat, particularly given the promising but early-stage data previously reported.
Regulatory Path
The success of ongoing trials and the potential for accelerated approval pathways will heavily influence Oryzon’s valuation, especially given the orphan drug designations for SCLC and AML.
Pipeline Expansion
How Oryzon balances its focus on iadademstat’s hematological and solid tumor applications, versus the broader epigenetics pipeline, will dictate long-term growth prospects.

Oryzon Bolsters BPD Patent Portfolio with US Allowance

Event summary

  • Oryzon Genomics received a Notice of Allowance from the USPTO for a patent application covering the use of vafidemstat for treating non-aggressive symptoms of Borderline Personality Disorder (BPD).
  • The patent, expected to be granted by 2040, complements Oryzon’s existing patent portfolio focused on aggression in BPD.
  • Corresponding patents have been granted or allowed in Australia, Europe, Japan, Mexico, Russia, Singapore, and South Africa.
  • ORYZON’s LSD1 inhibitor, vafidemstat, is advancing as a Phase III-ready asset for agitation/aggression in BPD.

The big picture

Oryzon’s strengthened patent position for vafidemstat represents a significant step in the development of novel treatments for BPD, a condition with limited therapeutic options. The company’s focus on epigenetics and CNS disorders positions it within a growing market segment, but success hinges on navigating the complexities of clinical trials and intellectual property protection. The Phase III trial for BPD will be a key inflection point for the company's valuation.

What we're watching

Commercialization
The success of Oryzon’s Phase III trial for BPD agitation/aggression will be critical in determining the commercial viability of vafidemstat and its ability to penetrate a market with significant unmet need.
Patent Defense
Given the value of the patent portfolio, Oryzon will likely face challenges from competitors seeking to develop similar LSD1 inhibitors, requiring ongoing vigilance and potential legal defense.
Pipeline Expansion
The company’s progress in expanding the application of vafidemstat to other CNS disorders, particularly those with genetic components, will influence its long-term growth trajectory and potential for precision medicine breakthroughs.

Oryzon Secures Key AML Combination Patent, Bolsters Iadademstat IP

Event summary

  • Oryzon Genomics has been granted U.S. Patent US12,564,559 B2 covering combinations of its LSD1 inhibitor, iadademstat, with venetoclax.
  • The patent, expiring in January 2039 (including patent term adjustment), protects methods of treating acute myeloid leukemia (AML) using these combinations.
  • Preliminary data from a Phase Ib clinical trial (ALICE-2) showed a 100% overall response rate (ORR) and 90% complete remission rate with iadademstat, venetoclax, and azacitidine.
  • Updated data from the ALICE-2 trial, involving approximately 15-16 patients, are expected to be presented at the EHA Annual Congress in June 2026.

The big picture

The patent grant strengthens Oryzon's IP position for iadademstat, a key asset in the competitive oncology market. The combination with venetoclax, a standard of care for AML, represents a significant opportunity, but the 100% ORR data, while promising, requires further validation. Success hinges on demonstrating sustained efficacy and navigating the complexities of regulatory approval and market access in a crowded therapeutic area.

What we're watching

Clinical Efficacy
The June EHA presentation will be critical to validating the initial 100% ORR data and assessing the long-term durability of responses in the ALICE-2 trial, which will inform the drug's commercial viability.
Regulatory Pathway
The potential for further patent term extensions related to regulatory review could significantly impact Oryzon’s market exclusivity and profitability, especially given the competitive landscape in AML treatment.
Competitive Dynamics
How the emergence of other LSD1 inhibitors or novel AML therapies will affect iadademstat’s adoption and Oryzon’s ability to maintain a differentiated position in the market remains to be seen.

Oryzon Bolsters Iadademstat Patent Portfolio in Mexico

Event summary

  • Oryzon Genomics secured a patent grant in Mexico covering combinations of its drug candidate, iadademstat, with PD-1/PD-L1 inhibitors.
  • The patent, filed in 2021, protects the use of iadademstat in treating cancer, specifically targeting small cell lung cancer (SCLC).
  • The patent is expected to provide protection until at least 2040, barring patent term extensions.
  • Oryzon now holds patents for these combinations in Australia, Europe, Japan, Mexico, and Russia.

The big picture

This patent grant strengthens Oryzon’s IP position for iadademstat, a key component of its oncology pipeline. The combination with PD-1/PD-L1 inhibitors represents a strategic shift towards immunotherapy, a rapidly growing segment of the cancer treatment market. Securing patent protection in multiple regions is essential for Oryzon to attract investment and potentially out-license the technology to larger pharmaceutical companies.

What we're watching

Clinical Progress
The success of ongoing Phase I/II trials in SCLC, particularly the NCI-sponsored study, will be crucial in validating the combination therapy and justifying the patent’s value.
Geographic Expansion
The pace at which Oryzon pursues patent applications and grants in other key jurisdictions will influence the drug’s commercial potential and competitive landscape.
Regulatory Risk
How the EMA and FDA view the combination therapy, and whether they will grant accelerated approval pathways, will significantly impact Oryzon’s ability to monetize the patent.

Oryzon Bolsters CNS Pipeline as Oncology Data Shows Promise

Event summary

  • Oryzon Genomics ended 2025 with $33.3 million in cash, following $60 million raised in the first half of 2025.
  • Rolando Gutierrez-Esteinou, M.D. has been appointed CMO for CNS programs to guide vafidemstat development.
  • Preliminary Phase I/II data presented at ASH showed 100% ORR and 90% strict CR in a 1L AML trial using a triple combination.
  • A new Phase II trial for aggression in autism spectrum disorder is planned, supported by an IPCEI EU Grant.
  • EMA approved a Phase II trial in essential thrombocythemia, named IDEAL.

The big picture

Oryzon's focus on epigenetics positions it within a growing field targeting disease mechanisms rather than just symptoms. The strong preliminary AML data, coupled with the cash infusion, suggests a potential inflection point for the company, but the success of vafidemstat, particularly its Phase III trial, remains the key determinant of long-term value. The reliance on grant funding for the autism trial highlights the challenges of securing capital in a competitive biotech landscape.

What we're watching

Regulatory Risk
The FDA’s continued guidance on the Phase III PORTICO-2 trial will dictate the timeline and potential success of vafidemstat’s development, and any further requests for data could delay approval.
Clinical Execution
The rapid enrollment and interim data presentation at EHA for the AML trial will be crucial in validating the triplet combination’s efficacy and safety profile, potentially influencing future development strategies.
Financial Runway
Oryzon’s $33.3 million cash position will need to sustain ongoing clinical trials and development activities, and securing additional funding may become necessary if trials encounter delays or unexpected costs.

Oryzon Secures EMA Approval to Advance iadademstat in Essential Thrombocythemia

Event summary

  • Oryzon Genomics received European Medicines Agency (EMA) approval to initiate a Phase II study (IDEAL) of iadademstat for essential thrombocythemia (ET).
  • The study will enroll adult ET patients resistant or intolerant to hydroxyurea, conducted across multiple sites in Spain.
  • Iadademstat, an LSD1 inhibitor, will be administered for up to 24 weeks, with a potential 24-week extension.
  • Preliminary data from trials combining iadademstat with azacitidine and venetoclax showed a 100% overall response rate (ORR) and 90% strict complete remission (CR) rate in acute myeloid leukemia (AML).

The big picture

Oryzon's strategy to expand iadademstat's use beyond oncology into hematology addresses a significant clinical need, as a substantial portion of ET patients develop resistance or intolerance to existing treatments. The company's focus on LSD1 inhibition, validated by positive results with other inhibitors, positions iadademstat as a potentially differentiated therapeutic option. However, the success of the IDEAL trial is crucial to realizing this potential and justifying the investment in a broader epigenetic pipeline.

What we're watching

Clinical Efficacy
The IDEAL trial's results will be critical in determining if iadademstat's LSD1 inhibition mechanism translates to meaningful clinical benefit in ET patients, particularly given the unmet need for alternatives to hydroxyurea.
Regulatory Pathway
Success in the Phase II trial will dictate the speed and likelihood of a potential market authorization application, which could significantly impact Oryzon’s valuation.
Pipeline Expansion
How Oryzon balances the advancement of iadademstat across multiple oncology and hematology indications will influence resource allocation and overall development timelines.

Oryzon to Present at Key Epigenetics and Biotech Forums

Event summary

  • Oryzon Genomics will participate in Bio-Neuroscience 2026 in Amsterdam (Feb 24-27).
  • The company will also attend the SmallCap Event 20th Edition in Paris (March 17).
  • Oryzon will be present at BIO-Europe Spring 2026 in Lisbon (March 23-25).
  • A panel discussion featuring Oryzon management is scheduled for March 25 at the LSX World Congress Europe in Lisbon (14:00 GMT).

The big picture

Oryzon’s participation in these events underscores its efforts to broaden investor awareness and secure funding for its clinical pipeline. As a European leader in epigenetics, the company faces competition from larger pharmaceutical players investing in similar technologies, necessitating proactive investor relations. The company’s focus on CNS disorders and oncology, two areas with significant unmet medical need, positions it for potential growth but also exposes it to regulatory and clinical trial risks.

What we're watching

Pipeline Visibility
Increased public appearances suggest Oryzon is actively seeking to raise profile of its Phase III-ready vafidemstat program, potentially to attract licensing partners or prepare for a future IPO.
Investor Sentiment
The SmallCap Event participation will be a key indicator of investor appetite for smaller-cap biotech firms, particularly those with early-stage CNS programs.
Clinical Data
The panel discussion at LSX World Congress Europe will likely focus on the ongoing clinical trials, and the quality of the data presented will significantly influence near-term valuation.

Oryzon Taps Atai Exec to Drive CNS Program into Phase III

Event summary

  • Rolando Gutierrez-Esteinou, M.D. has been appointed Chief Medical Officer for CNS Programs at Oryzon Genomics.
  • Dr. Gutierrez-Esteinou previously served as CMO at Atai Life Sciences.
  • He brings over 20 years of experience in CNS drug development, including late-stage execution and regulatory strategy.
  • Oryzon plans to advance vafidemstat, its lead CNS program, into Phase III trials for agitation and aggression in borderline personality disorder.
  • Dr. Michael Ropacki, the previous CMO–CNS, is being recognized for his six years of service.

The big picture

Oryzon’s move to recruit a seasoned executive like Dr. Gutierrez-Esteinou signals a heightened focus on advancing its vafidemstat program, which targets a significant unmet need in CNS disorders. The company’s strategy of leveraging epigenetic mechanisms represents a potentially disruptive approach to treating psychiatric conditions, but also carries regulatory and clinical execution risks. This appointment underscores the increasing trend of biopharma companies seeking specialized expertise to navigate the complexities of CNS drug development.

What we're watching

Clinical Execution
The success of Oryzon’s Phase III trial for vafidemstat will hinge on Dr. Gutierrez-Esteinou’s experience in late-stage CNS development, given the complexity of BPD and the need for robust efficacy data.
Regulatory Pathway
The FDA and EMA will likely scrutinize Oryzon’s epigenetic approach to CNS disorders, and Dr. Gutierrez-Esteinou’s prior regulatory interactions will be critical in navigating potential hurdles.
Pipeline Expansion
Oryzon’s stated intention to expand vafidemstat’s clinical development into autism and schizophrenia will require significant resources and may dilute focus from the initial BPD indication.

Oryzon Advances LSD1 Inhibitor Study in SCLC with Yale Collaboration

Event summary

  • Oryzon Genomics initiated a Phase Ib investigator-initiated trial combining iadademstat, radiotherapy, and atezolizumab for extensive stage small cell lung cancer (ES-SCLC).
  • The trial, led by Yale University (NCT07113691), will enroll patients with progressive or recurrent ES-SCLC who have previously received platinum-based chemotherapy.
  • The study aims to evaluate safety, tolerability, and efficacy, utilizing paired biopsies to analyze tumor and microenvironment changes.
  • Dr. Anne Chiang at Yale University is the Principal Investigator for the study.

The big picture

Small cell lung cancer remains a challenging oncology indication with limited treatment options and a high mortality rate. Oryzon's strategy of combining its LSD1 inhibitor, iadademstat, with established therapies like atezolizumab and radiotherapy represents a targeted approach to address this unmet need. The reliance on investigator-initiated trials allows Oryzon to explore novel combinations with lower upfront investment, but also introduces dependencies on external researchers and potentially slower development timelines.

What we're watching

Clinical Efficacy
The trial's early data will be crucial in determining whether the combination of iadademstat, radiotherapy, and atezolizumab demonstrates meaningful clinical benefit in a heavily pre-treated ES-SCLC population, given the aggressive nature of the disease.
Biomarker Identification
The paired biopsy approach employed by Yale University could yield valuable insights into predictive biomarkers, potentially guiding patient selection and optimizing treatment strategies for iadademstat in SCLC.
Regulatory Pathway
Success in this investigator-initiated trial, particularly if it reveals a clear efficacy signal, could accelerate Oryzon's plans to pursue a larger, company-sponsored clinical trial and ultimately influence the regulatory pathway for iadademstat in SCLC.

Oryzon Bolsters Vafidemstat Patent Protection in Japan

Event summary

  • Oryzon Genomics received a ‘Decision to grant’ from the Japanese Patent Office for patent application JP2023-136283 covering vafidemstat’s use in treating aggression and social withdrawal.
  • The granted patent, expected to remain in force until at least 2038 (excluding potential extensions), covers treatment of aggression and social withdrawal.
  • Oryzon already holds corresponding patents or allowances in Europe, Australia, Canada, Hong Kong, Israel, South Korea, Malaysia, the Philippines, and Russia.
  • The company is preparing Phase III trials for BPD aggression and Phase II trials for ASD and schizophrenia, utilizing vafidemstat.

The big picture

This patent grant strengthens Oryzon’s IP position for vafidemstat, a key asset in the company’s pipeline targeting CNS disorders. The company’s focus on epigenetics and personalized medicine represents a growing trend in biopharmaceutical development, but faces challenges in demonstrating clinical efficacy and navigating complex regulatory pathways. Securing patent protection in key markets like Japan is essential for maximizing the commercial value of vafidemstat and supporting Oryzon’s long-term growth strategy.

What we're watching

Clinical Execution
The success of Oryzon’s upcoming Phase III trial in BPD will be critical to validating vafidemstat’s efficacy and commercial potential, given the relatively high unmet need in this patient population.
Regulatory Landscape
The speed of regulatory approval in Japan, a key market, will influence Oryzon’s overall commercialization timeline and revenue projections for vafidemstat.
Patent Defense
Oryzon will need to actively defend its patent portfolio against potential challenges, as competitors may seek to develop similar LSD1 inhibitors for CNS disorders.

Oryzon to Intensify Investor Outreach Amidst CNS Pipeline Advancement

Event summary

  • Oryzon Genomics will present at the Sachs Neuroscience Innovation Forum on January 11th in San Francisco.
  • The company will also participate in the J.P. Morgan Healthcare Conference from January 12th to 15th in San Francisco.
  • Oryzon’s management will attend the Allinvest Securities Biomed Forum in Paris on January 29th.
  • Management will be available for one-on-one meetings at all listed events.

The big picture

Oryzon’s increased investor outreach signals a heightened focus on securing funding and demonstrating progress in its clinical pipeline, particularly for vafidemstat. The company's positioning as a leader in epigenetics within the CNS and oncology spaces is increasingly reliant on delivering positive clinical trial data and attracting institutional investment in a competitive biotech landscape. Participation in these conferences is a standard practice for companies seeking to raise capital and build investor confidence.

What we're watching

Pipeline Progress
The presentations will likely focus on the Phase III-ready vafidemstat program for CNS disorders, and investor interest will hinge on data updates and regulatory timelines.
Financial Capacity
Given the costs associated with Phase III trials, Oryzon’s ability to secure additional funding or partnerships will be critical to sustaining its development pipeline.
Market Reception
The reception of Oryzon’s management at these high-profile conferences will influence investor sentiment and potentially impact the company’s valuation.

Oryzon Bolsters Iadademstat Patent Portfolio in Japan

Event summary

  • Oryzon Genomics secured a Decision to Grant for a patent application (JP2021-557187) in Japan covering combinations of iadademstat with PD-1/PD-L1 inhibitors.
  • The patent, expected to remain in force until at least 2040, covers combinations for cancer therapy.
  • Oryzon now holds patent protection for these combinations in Europe, Japan, Australia, and Russia.
  • The patent application relates to the clinical use of iadademstat in combination with immune checkpoint inhibitors for small cell lung cancer (SCLC).

The big picture

This patent grant strengthens Oryzon's intellectual property position for iadademstat, a key asset in their oncology pipeline. The focus on combinations with PD-1/PD-L1 inhibitors reflects the growing importance of immuno-oncology and the potential for synergistic effects. Securing patent protection in Japan, a significant pharmaceutical market, is a strategic win, but the ultimate value will depend on clinical trial success and commercial execution.

What we're watching

Commercialization
The speed at which Oryzon can translate this patent protection into commercial partnerships or licensing deals will be a key indicator of the asset's value.
Clinical Progress
The ongoing Phase I/II trial in combination with PD-L1 inhibitors will need to demonstrate meaningful efficacy to justify the patent’s value and Oryzon’s investment.
Competitive Landscape
How competitors are positioning their own epigenetic therapies, particularly in SCLC, will influence Oryzon's ability to capture market share.
CID: 228